文献速递核素与放射性配体治疗肿瘤 PET/CT

比较镓-68、镥-177和锕-225标记的PSMA-TO-1与PSMA-617

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225.
PubMed 文献 · EJNMMI Res · 2022-10-01

在皮下肿瘤小鼠中比较68Ga和177Lu标记的PSMA-TO-1、PSMA-617与PSMA-11的生物分布,并在播散性前列腺癌小鼠模型中比较225Ac-PSMA-TO-1与225Ac-PSMA-617治疗后的生存期,同时报告3例前列腺癌患者的177Lu-PSMA-TO-1/-617剂量学数据。68Ga-PET肿瘤摄取以PSMA-617最高、PSMA-TO-1次之、PSMA-11最低;177Lu-PSMA-TO-1肿瘤摄取在治疗后1周内趋于更高但所有时间点p>0.13,且小鼠肾脏剂量为PSMA-617的26倍。225Ac-PSMA-TO-1组生存期长于225Ac-PSMA-617组和未治疗组。

要点

  • 小鼠68Ga-PET肿瘤摄取:PSMA-617最高,PSMA-TO-1次之,PSMA-11最低。
  • 小鼠177Lu-PSMA-TO-1肿瘤摄取在治疗后1周内趋于高于PSMA-617,但各时间点p>0.13。
  • 小鼠中PSMA-TO-1肾脏剂量为PSMA-617的26倍;225Ac-PSMA-TO-1组生存期17.8周,长于PSMA-617组14.5周和未治疗组7.7周(p<0.0001)。

核心结论

  • PSMA-TO-1的肿瘤摄取在临床前和临床环境中均趋于高于PSMA-617。
  • 尽管肾脏摄取增加,225Ac-PSMA-TO-1治疗小鼠较225Ac-PSMA-617带来显著生存获益。
  • 在人体中,PSMA-TO-1剂量学估算提示肿瘤吸收剂量增加,但肾脏、唾液腺和骨髓也受到更高辐射剂量;因此进一步临床使用前需要更多临床前研究。

研究设计与样本

  • 在皮下C4-2异种移植瘤小鼠中连续多日采集68Ga-PSMA-TO-1/-617/-11的PET图像。
  • 50只皮下肿瘤小鼠分别接受30 MBq的177Lu-PSMA-617或177Lu-PSMA-TO-1,于1、4、24、48和168小时处死行离体伽马计数和生物分布。
  • 经心内接种建立播散性病灶的小鼠分别接受40 kBq的225Ac-PSMA-617、225Ac-PSMA-TO-1或不予治疗,随访生存期。
  • 3例转移性去势抵抗性前列腺癌患者在同情用药下接受500 MBq的177Lu-PSMA-TO-1用于剂量学计算,采集平面图像并附加SPECT/CT采集。

主要发现

  • 小鼠68Ga标记药物的PET肿瘤摄取以PSMA-617最高,其次为PSMA-TO-1和PSMA-11。
  • 离体伽马计数显示177Lu-PSMA-TO-1的肿瘤摄取在治疗后1周内趋于高于PSMA-617,所有时间点p>0.13。
  • 小鼠中PSMA-TO-1的肾脏摄取增加,肾脏剂量为PSMA-617的26倍。
  • 单周期225Ac-PSMA-TO-1治疗小鼠的生存期长于225Ac-PSMA-617治疗小鼠和未治疗小鼠,分别为17.8、14.5和7.7周(p<0.0001)。
  • 患者#01/#02/#03的177Lu-PSMA-TO-1肾脏、唾液腺、骨髓和肿瘤剂量系数(Gy/GBq,肿瘤为均值±标准差)分别为2.5/2.4/3.0、1.0/2.5/2.3、0.14/0.11/0.10和0.42±0.03/4.45±0.07/1.8±0.57。

临床怎么用

  • 原文结论指出,进一步临床使用前需要更多临床前研究。

局限性

  • 小鼠中177Lu-PSMA-TO-1肿瘤摄取在治疗后1周内趋于更高,但所有时间点p>0.13。
  • 原文结论指出,进一步临床使用前需要更多临床前研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PSMA-TO-1 ("Tumor-Optimized-1") is a novel PSMA ligand with longer circulation time than PSMA-617. We compared the biodistribution in subcutaneous tumor-bearing mice of PSMA-TO-1, PSMA-617 and PSMA-11 when labeled with 68Ga and 177Lu, and the survival after treatment with 225Ac-PSMA-TO-1/-617 in a murine model of disseminated prostate cancer. We also report dosimetry data of 177Lu-PSMA-TO1/-617 in prostate cancer patients. METHODS: First, PET images of 68Ga-PSMA-TO-1/-617/-11 were acquired on consecutive days in three mice bearing subcutaneous C4-2 xenografts. Second, 50 subcutaneous tumor-bearing mice received either 30 MBq of 177Lu-PSMA-617 or 177Lu-PSMA-TO-1 and were sacrificed at 1, 4, 24, 48 and 168 h for ex vivo gamma counting and biodistribution. Third, mice bearing disseminated lesions via intracardiac inoculation were treated with either 40 kBq of 225Ac-PSMA-617, 225Ac-PSMA-TO-1, or remained untreated and followed for survival. Additionally, 3 metastatic castration-resistant prostate cancer patients received 500 MBq of 177Lu-PSMA-TO-1 under compassionate use for dosimetry purposes. Planar images with an additional SPECT/CT acquisition were acquired for dosimetry calculations. RESULTS: Tumor uptake measured by PET imaging of 68Ga-labeled agents in mice was highest using PSMA-617, followed by PSMA-TO-1 and PSMA-11. 177Lu-PSMA tumor uptake measured by ex vivo gamma counting at subsequent time points tended to be greater for PSMA-TO-1 up to 1 week following treatment (p > 0.13 at all time points). This was, however, accompanied by increased kidney uptake and a 26-fold higher kidney dose of PSMA-TO-1 compared with PSMA-617 in mice. Mice treated with a single-cycle 225Ac-PSMA-TO-1 survived longer than those treated with 225Ac-PSMA-617 and untreated mice, respectively (17.8, 14.5 and 7.7 weeks, respectively; p < 0.0001). Kidney, salivary gland, bone marrow and mean ± SD tumor dose coefficients (Gy/GBq) for 177Lu-PSMA-TO-1 in patients #01/#02/#03 were 2.5/2.4/3.0, 1.0/2.5/2.3, 0.14/0.11/0.10 and 0.42 ± 0.03/4.45 ± 0.07/1.8 ± 0.57, respectively. CONCLUSIONS: PSMA-TO-1 tumor uptake tended to be greater than that of PSMA-617 in both preclinical and clinical settings. Mice treated with 225Ac-PSMA-TO-1 conferred a significant survival benefit compared to 225Ac-PSMA-617 despite the accompanying increased kidney uptake. In humans, PSMA-TO-1 dosimetry estimates suggest increased tumor absorbed doses; however, the kidneys, salivary glands and bone marrow are also exposed to higher radiation doses. Thus, additional preclinical studies are needed before further clinical use.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Meyer C, Prasad V, Stuparu A, et al. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 2022. PMID: 36182983. doi:10.1186/s13550-022-00935-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。